KLRC1 and neoplasm: Moreover, in B16/F1 tumor tissues collected on 17d and 19d postinoculation, NKG2A-expressing CD8+ T and NK cells accounted for 51–56% of NKG2A-expressing immune cells, and IL-2Rβγ-expressing CD8+ T and NK cells accounted for 67–75% of IL-2Rβγ-expressing immune cells (Figure S3(A)), while NKG2A+IL2Rβγ+ CD8+ T cells and NKG2A+IL2Rβγ+ NK cells accounted for 38.6–69% and 18% of NKG2A- and/or IL-2Rβγ-expressing tumor-infiltrated immune cells (Figure S4), indicating high co-expression of NKG2A and IL-2Rβγ in CD8+ T and NK cells in B16/F1 tumor tissues.